Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
OBJECTIVE
Recent studies have demonstrated that pioglitazone (PIO) has beneficial effects on insulin sensitivity compared with placebo in patients with type 2 diabetes. The effects of PIO and gliclazide (GLIC)-based therapy on insulin sensitivity have not previously been directly compared. This analysis aimed to compare the effects of 52 weeks of treatment with PIO (30-45 mg/day) and GLIC (80-320 mg/day), both titrated to maximum tolerable doses, as monotherapy or in combination with metformin (MET), on insulin sensitivity and lipid parameters known to be related to insulin sensitivity in patients with type 2 diabetes.


METHODS
We performed an analysis of 1,880 patients with inadequately controlled type 2 diabetes (HbA1c 7.5-11.0%) who were participants in two parallel-group, double-blind, double-dummy, randomised, multicentre, clinical trials. Measures of insulin sensitivity and lipids were assessed.


RESULTS
The PIO- and GLIC-based regimens produced similar levels of glycaemic control (HbA1c). In both trials, insulin sensitivity as assessed using the homeostasis model assessment was improved in patients receiving PIO, but decreased in those receiving GLIC (mean change, baseline to endpoint: PIO 15.5, GLIC -15.6; p<0.001 and PIO+MET 18.9, GLIC+MET -5.3; p<0.001). Improvements in the atherogenic index of plasma (mean change: PIO -0.17, GLIC -0.08; p<0.001 and PIO+MET -0.17, GLIC+MET -0.02; p<0.001), triglycerides (mean change, mmol/l: PIO+MET -0.62, GLIC+MET -0.22; p<0.001) and NEFA (mean change, mmol/l: PIO+MET -0.12, GLIC+MET-0.05; p<0.001) were greater in PIO-treated patients than in patients receiving GLIC.


CONCLUSIONS
The PIO-based regimens resulted in improved insulin sensitivity and more favourable insulin sensitivity-related lipid profiles compared with the GLIC-based regimens. These benefits may be important in the management of cardiovascular risk in patients with type 2 diabetes.
Charbonnel
B
B
Endocrinology Clinic, Hotel Dieu Hospital, Nantes, France.
Roden
M
M
Urquhart
R
R
Mariz
S
S
Johns
D
D
Mihm
M
M
Widel
M
M
Tan
M
M
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
D001786:Blood Glucose; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000077205:Pioglitazone; D045162:Thiazolidinediones
Diabetes. 1997 Jun;46(6):983-8
9166669
Diabetes Care. 2001 May;24(5):933-41
11347757
Clin Chem. 2003 Nov;49(11):1873-80
14578319
Diabetes Res Clin Pract. 1991;14 Suppl 2:S21-36
1794262
J Clin Endocrinol Metab. 2003 Apr;88(4):1637-45
12679450
Diabet Med. 2004 Jun;21(6):568-76
15154941
Atherosclerosis. 1996 Jan 26;119(2):235-45
8808500
J Clin Endocrinol Metab. 2004 Mar;89(3):1481-4
15001651
Diabetes Care. 2003 Sep;26(9):2588-94
12941723
J Clin Endocrinol Metab. 2001 Nov;86(11):5412-9
11701715
Pharmacol Ther. 2002 Jul;95(1):47-62
12163127
Diabetes Care. 2004 Jun;27(6):1487-95
15161807
Diabetes Care. 1998 Dec;21(12):2191-2
9839117
Diabetes. 1999 Sep;48(9):1836-41
10480616
Diabetologia. 2000 Feb;43(2):148-55
10753035
Lancet. 1998 Sep 12;352(9131):837-53
9742976
Clin Biochem. 2001 Oct;34(7):583-8
11738396
Diabetes Care. 2001 Apr;24(4):710-9
11315836
Arch Intern Med. 2001 Dec 10-24;161(22):2685-92
11732933
Diabet Med. 1998 Apr;15(4):297-303
9585394
BMJ. 1998 Mar 14;316(7134):823-8
9549452
Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):167-74
15386821
JAMA. 2001 May 16;285(19):2486-97
11368702
J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10
10902785
Circulation. 1996 Jan 1;93(1):54-9
8616941
Clin Ther. 2003 Apr;25(4):1074-95
12809958
Clin Chem. 2004 Jul;50(7):1184-8
15117857
Am J Cardiol. 1995 Jun 15;75(17):1189-95
7778537
Circulation. 1998 Mar 17;97(10):996-1001
9529268
Metabolism. 1984 Jan;33(1):68-75
6361449
Diabetes Care. 2002 Jul;25(7):1135-41
12087010
Diabetes Care. 2000 Jan;23(1):57-63
10857969
J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91
12050251
J Clin Invest. 1996 Jun 15;97(12):2859-65
8675698
Circulation. 1996 May 15;93(10):1809-17
8635260
Diabetes. 1999 Aug;48(8):1600-6
10426379
Diabetes Care. 2003 Aug;26(8):2426-32
12882874
Diabetes. 1999 Feb;48(2):358-64
10334314
Diabetologia. 1999 Jan;42(1):113-6
10027589
Diabetes Care. 2004 Jul;27(7):1647-53
15220241
Diabet Med. 2005 Apr;22(4):399-405
15787663